News Cardiol Therapeutics Inc.

Stocks

CRDL

CA14161Y2006

Biotechnology & Medical Research

Delayed Toronto S.E. 14:21:16 2026-10-22 EDT			5-day change	1st Jan Change
1.620 ^CAD	-2.41%		+1.25%	+23.66%

09-23	Cardiol Therapeutics Achieves Phase III Maveric Enrollment Target Ahead of Schedule and Expands Pivotal Trial	CI
09-23	Cardiol Therapeutics Inc. Achieves MAVERIC Enrollment Target And Expands Pivotal Trial Evaluating CardiolRx	CI

All News

Mentions Relevance

10-08	Ellis Martin Report: Cardiol Therapeutics (TOR:CRDL) CEO David Elsley Discusses Phase III MAVERIC and What Comes Next for CardiolRx	AQ
09-23	Cardiol Therapeutics Achieves Phase III Maveric Enrollment Target Ahead of Schedule and Expands Pivotal Trial	CI
09-23	Cardiol Therapeutics : Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™’s Efficacy	PU
09-23	Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy	PR
09-23	Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy	AQ
09-23	Cardiol Therapeutics Inc. Achieves MAVERIC Enrollment Target And Expands Pivotal Trial Evaluating CardiolRx	CI
09-16	Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds	PR
09-16	Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds	AQ
09-10	Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission	PR
09-10	Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission	AQ
09-09	Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference	PR
09-09	Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
08-12	Cardiol Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-05	Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference	PR
08-05	Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference	AQ
07-14	Cardiol Therapeutics : rsquo; Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association	PU
07-14	Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association	PR
07-14	Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association	AQ
07-09	Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit	PR
07-09	Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit	AQ
06-25	Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders	PR
06-25	Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders	AQ
06-23	Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT	PR
06-23	Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT	AQ
05-14	Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ	PR